PRRT2 and uveal melanoma: Novel therapies for metastatic uveal melanoma include drugs targeting the 1) MAPK pathway, such as the selective MEK1/2 inhibitor, selumetinib; 2) PKC pathway, such as AEB071 (Pelster et al., 2021) and IDE196 (i.e., darovasertib (Ideayabio, 2022a)); 3) phosphoinositide-3-kinase (PI3K) and insulin-like growth factor-1(IGF)-1/insulin-like growth factor type 1 receptor (IGF-1R) pathways, e.g., pasireotide and 4) Hippo-Yes-associated protein 1(YAP) pathway (Martin et al., 2013).